Marina Biotech, Inc. is a fully integrated, commercial stage biopharmaceutical company delivering proprietary drug therapeutics for significant unmet medical needs in the U.S., Europe and additional markets. Our portfolio of products focuses on fixed dose combinations FDC in hypertension, arthritis, pain and oncology allowing for innovative solutions to such unmet medical needs. Our approach is meant to reduce clinical risk and accelerate time to market by shortening the clinical development program through leveraging what is already known or can be learned in our proprietary Patient Level Database. We currently have one commercial and three clinical development programs underway: i Prestalia , a single pill FDC of perindopril and amlodipine, which has been approved by the FDA and is actively marketed in the U.S. ii our next generation celecoxib program drug candidates for the treatment of acute and chronic pain, IT and IT , each of which is an FDC of celecoxib and either lisinopril IT or olmesartan IT iii CEQ , an oral delivery of small interfering RNA against beta catenin, combined with IT to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis and iv CEQ combined with IT to treat Colorectal Cancer.
Quote | Moderna Inc. (NASDAQ:MRNA)
Last: | $122.185 |
---|---|
Change Percent: | 0.86% |
Open: | $122.52 |
Close: | $121.14 |
High: | $124.055 |
Low: | $120.44 |
Volume: | 821,980 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Moderna Inc. (NASDAQ:MRNA)
2024-07-21 07:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Bristol-Myers Squibb - Investors Are Too Long-Term Focused Bristol-Myers Squibb Is A Bargain Now AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings Dividend Roundup: Gold...
2024-07-19 04:57:22 ET Summary In this article, I review my investments in mid and large-cap value stocks since October 2023. The portfolio returned a 14% return, narrowly beating the S&P equal-weighted index, but underperforming the S&P 500. 4 out of 10 picks beating the ...
Message Board Posts | Moderna Inc. (NASDAQ:MRNA)
Subject | By | Source | When |
---|---|---|---|
Cathie Wood's ARK Innovation ETF buys shares of | axelvento | investorshub | 05/01/2023 4:39:04 AM |
Believe in what | Vexari | investorshub | 05/01/2023 4:25:38 AM |
the important thing is to believe not to hope! | axelvento | investorshub | 05/01/2023 4:14:06 AM |
The thought of overthinking without explanation | Vexari | investorshub | 04/30/2023 8:03:20 PM |
Without understanding | Vexari | investorshub | 04/29/2023 9:23:49 PM |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...